2022 Hybrid Research Symposium Posters

The 2022 NETRF Hybrid Research Symposium poster session was held at the Boston meeting for presenters that attended in-person, however, all posters were viewable online through the virtual Symposium platform. 

Please note that some presenters chose not to post their presentations online following the meeting and have been respectfully omitted here.

Select Session

Update on Clinical Evaluation of 3-[18F]fluoro-p-hydroxyphenethylguanidine ([18F]3F-PHPG) for Localization of Paraganglioma and Pheochromocytoma using Positron Emission Tomography (PET)

Presenter: Raffel

SV2A PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Neuroendocrine Tumors

Presenter: Hao

Survival differences of lung neuroendocrine tumors in California by sociodemographic, clinicopathologic, and treatment factors

Presenter: Mulvey

Proximity to Healthcare Providers, Bankruptcy, and Relationship Status within Neuroendocrine Cancer Patients

Presenter: Skill

PAK4/NAMPT inhibitor KPT-9274 synergizes with Sunitinib in Pancreatic Neuroendocrine Tumor Cellular Models

Presenter: Uddin

Monitoring the treatment of AR42J tumor-bearing mice with 225Ac-Crown-TATE

Presenter: Wasylishen

Image-guided delivery of temozolomide to SSTR2 expressing cells

Presenter: Aghaamiri

IgG4 related mesenteric fibrosis in small bowel neuroendocrine neoplasms

Presenter: Kaçmaz

Evaluation of DOTATATE-PET After Two Cycles of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NETs)

Presenter: Duan

Endocrine-exocrine signaling drives pancreatic cancer progression

Presenter: Muzumdar

Effect of Epigenetic Treatment on SST2 Expression in Neuroendocrine Tumor Patients

Presenter: Refardt

Dissecting neuroendocrine mixed tumors by single cell RNA-seq

Presenter: Tirosh

A novel anti-SSTR bispecific T-cell engager (BiTE®)-like molecule for the treatment of neuroendocrine tumors

Presenter: Pelle

3p C NETA TATE: A versatile somatostatin analogue for Al 18 F labeled and therapeutic SSTR2 targeting radiopharmaceuticals

Presenter: Cleeren